eligibility_summary
Eligible: Patients in Japan with relapsed/refractory CLL (2L+) per iwCLL at consent, treated with venetoclax±rituximab for 24 months with no other concurrent CLL therapy, expected to attend a visit 3 months after completing the 24‑month course. Exclude: missing venetoclax start/end or continuation data, participation in other clinical trials.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Observational real-world study in Japan (2L+ CLL) assessing uMRD after 24 months of venetoclax +/- rituximab. Venetoclax (ABT-199) is an oral small-molecule BCL-2 inhibitor that blocks the anti-apoptotic BCL-2 protein, restoring mitochondrial (intrinsic) apoptosis in malignant B-cells. Rituximab is an IV chimeric anti-CD20 IgG1 monoclonal antibody that targets CD20 on B-cells, causing B-cell depletion via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and direct apoptosis. Targets/pathways: CLL B-cells, BCL-2-regulated apoptotic pathway, CD20 antigen on B-cells.